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Local Delivery of Gene-Modifying Triplex-Forming
Molecules to the Epidermis
Faye A. Rogers1, Rong-Hua Hu2 and Leonard M. Milstone2
Epidermal keratinocytes are particularly suitable candidates for in situ gene correction. Intraperitoneal admin-
istration of a triplex-forming oligonucleotide (TFO) was previously shown to introduce DNA base changes in a
reporter gene in skin, without identifying which cells had been targeted. We extend those previous experiments
using two triplex-forming molecules, a peptide nucleic acid–antennapedia (PNA-Antp), and a TFO (AG30), as well
as two lines of transgenic mice that have the chromosomally integrated lsupFG1 shuttle-reporter transgene.
Successful in vivo genomic modification occurs in the epidermis and dermis in CD1 transgenic mice following
either intraperitoneal or intradermal delivery of the PNA-Antp conjugate. FITC-PNA-Antp accumulates in nuclei of
keratinocytes, and, after intradermal delivery of the PNA-Antp, chromosomally modified, keratin 5–positive basal
keratinocytes persist for at least 10 days. In hairless (SKH1) mice with the lsupFG1 transgene, intradermal delivery
of the TFO, AG30, introduces gene modifications in both tail and back skin, and these chromosomal
modifications persist in basal keratinocytes for 10 days. Hairless mice should facilitate comparison of various
targeting agents and methods of delivery. Gene targeting by repeated local administration of oligonucleotides
may prove clinically useful for judiciously selected disease-causing genes in the epidermis.
Journal of Investigative Dermatology (2013) 133, 685–691; doi:10.1038/jid.2012.351; published online 27 September 2012
INTRODUCTION
Disease-causing mutant epidermal keratinocytes are particu-
larly suitable candidates for localized gene-targeting strate-
gies. First, keratinocytes are accessible, making targeting
in situ possible and repeated targeting practical. Acces-
sibility also makes targeting ex vivo followed by selection
of correctly targeted cells and transplantation feasible
(Petek et al., 2010). Second, even localized or rare correc-
tions can be amplified by improved biological fitness. For
example, a single corrected cell can expand to a 41-cm patch
of normal skin in spontaneous, epidermal revertent mosai-
cism, a naturally occurring phenomenon now recognized in
ichthyotic (Choate et al., 2010) and blistering genodermatoses
(Jonkman et al., 1997; Smith et al., 2004; Jonkman and
Pasmooij, 2009). Third, a number of genodermatoses have
regional variability in expression or phenotypic severity,
implying that successful targeting of keratinocytes in a
localized area could be clinically beneficial even to a
patient with generalized cutaneous disease.
Heritable, sequence-specific targeting of DNA by triplex-
forming oligonucleotides (TFOs) was first demonstrated
20 years ago using a psoralen-linked TFO that bound to
and mutated l phage DNA (Havre et al., 1993). Since then,
TFOs have been used to target extrachromosomal DNA in
mammalian cells (Sandor and Bredberg, 1994; Wang et al.,
1995), chromosomes of mammalian cells (Gunther et al.,
1995; Vasquez et al., 1999), and, following intraperitoneal
injections, DNA of many organs, including skin (Vasquez
et al., 2000). TFOs by themselves induce mutations or recom-
binations in DNA (Sandor and Bredberg, 1995; Faruqi et al.,
1996) and require the participation of DNA-repair proteins
(Wang et al., 1996; Faruqi et al., 2000; Vasquez et al., 2002).
TFOs administered along with short, homologous donor oligo-
nucleotides can introduce predictable, sequence-specific base
changes in genes in close proximity to the triplex (Chan et al.,
1999). The combination of a triplex-forming molecule (TFM)
and an adjacent homologous donor oligonucleotide has been
used to restore function to mutant hypoxanthine phosphori-
bosyl transferase (Majumdar et al., 2008) and to predictably
change the sequence in b-globin (Chin et al., 2008; Lonkar
et al., 2009) and C-C chemokine receptor 5 (Schleifman et al.,
2011).
Clinical success of any gene-targeting strategy will be
dependent on delivery of the oligomer to target cells or tissue,
and each target cell may present unique obstacles. Some
progress has been made in improving TFO delivery by phy-
sical and chemical means. TFO-induced recombination
occurs in 1% of cultured cells following intranuclear injection
compared with only 0.003% following transfection with
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cationic lipids (Luo et al., 2000). Peptide nucleic acids (PNAs)
are more versatile TFMs than phosphodiester oligonucleotides,
but are difficult to deliver to cells. Coupling a PNA to a cell-
penetrating peptide, antennapedia (Antp), increases targeting
of the supFG1 gene 10–20-fold in cultured cells (Rogers et al.,
2004) and, after intraperitoneal injection, in bone marrow–
derived cells and whole tissues (Rogers et al., 2012). These
previous studies demonstrate that chromosomally integrated
supFG1 genes are well suited for evaluating sequence-specific
targeting of the reporter gene, because the supFG1 assay is
both quantitative and reproducible.
The goal of this report is to demonstrate that (a) site-specific
targeting occurs in keratinocyte DNA, (b) that chemically
distinctive TFMs can be used to target keratinocyte DNA, (c)
and that triplex-induced targeting can be achieved by local
delivery that is not dependent on the strain of mouse or skin
location. This will set the stage for quantitative comparisons of
different TFMs and/or local delivery methods.
RESULTS
For these experiments, we used transgenic mouse models that
contain multiple copies of the lsupFG1 shuttle vector inte-
grated into mouse chromosomal DNA (Figure 1). The vector
DNA can be isolated from mouse genomic DNA and pack-
aged into phage particles for subsequent analysis for induced
mutations. SupFG1 encodes an amber suppressor tRNA whose
function can be scored as a blue–white screen in indicator
bacteria. We used previously described oligomers that form
triplex structures with a purine-rich target sequence in supFG1
DNA. The PNA oligomer (PNA-Antp) forms a PNA:DNA:PNA
triplex invasion complex (Faruqi et al., 1998), whereas the
polypurine DNA oligomer, AG30, binds in the major groove
oriented parallel to the purine-rich strand of the supFG1
duplex (Vasquez et al., 2000) (Figure 1). These molecules
are known to induce site-specific targeting of the supFG1 gene
in various tissues of mice, but targeting of specific epithelial
cells has not been demonstrated.
Gene targeting in the epidermis and dermis following
intraperitoneal injection of triplex-forming PNAs
Intraperitoneal injections of phosphate-buffered saline (PBS),
PNA, or PNA-Antp were administered on days 1 and 3 to AV
supFG1 transgenic mice at a concentration of 20 mg kg 1
(115–150mg, depending on the size of the mouse) for each
dose. Ten days post treatment, tail skin was harvested and
analyzed for targeted mutations in the supFG1 gene. Mutation
frequencies in whole skin induced by PNA-Antp (34106)
were determined to be 6-fold over background, and signifi-
cantly more than that induced by the PNA molecule alone
(15106) (Figure 2). To examine the extent of targeting in
the individual skin layers, the epidermis was enzymatically
separated from the dermis prior to analysis. In those experi-
ments, systemic administration of the PNA-Antp conjugate
induced more genomic modification in both the epidermis
and dermis than the PNA alone or the PBS controls (Figure 2).
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Figure 1. Graphic summarizing experimental design and methods. AV and
SKHAV mice have the chromosomally integrated supFG1 reporter gene. The
peptide nucleic acids (PNAs) (used in the AV mice) form a strand-invasion
complex by binding to the homopurine strand at position 167–176 of the
supFG1 gene and generating a PNA:DNA:PNA triplex. The AG30, used in the
SKHAV mice, forms a triplex structure at positions 167–196 of supFG1. TFM,
triplex-forming molecule.
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Figure 2. Gene targeting in the epidermis and dermis of mice after
intraperitoneal delivery of triplex-forming peptide nucleic acids (PNAs).
AV mice received PNA, PNA-antennapedia(Antp), or phosphate-buffered
saline (PBS) by intraperitoneal injection. Ten days later, mutations were
measured in the supFG1 transgene recovered from genomic DNA of intact tail
skin or dispase-separated epidermis and dermis. Numbers over bars are mutant
plaques over total plaques counted. Frequencies are averages ±SEM from
individual mice. Inset shows sequence analysis of mutations induced by
treatment with PNA-Antp. The PNA target site is underlined and (þ ) and ( )
represent single base-pair insertions and deletions, respectively.
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We analyzed mutations that were induced following PNA-
Antp treatment by sequencing the shuttle reporter obtained
from both the epidermis and dermis. The majority of the
mutations were located precisely within the PNA-binding site
of supFG1 and consisted mainly of single base substitutions,
insertions, or deletions, as previously observed in other cells
and tissues (Rogers et al., 2012) and consistent with the occur-
rence of sequence-directed genome modification (Figure 2,
inset). In contrast, mutations in the PBS controls are spread
over the entire supFG1 sequence, as previously reported
(Gunther et al., 1995; Vasquez et al., 2001).
Gene targeting in the epidermis following intradermal injection
of triplex-forming PNAs
To minimize the quantity of TFMs needed to target cells in
skin and reduce potential for targeting irrelevant cells, we
treated AV mice with two 10-mg doses of PNA or PNA-Antp by
intradermal injection into the tail on days 1 and 3. Ten days
after treatment, tail-skin samples were harvested and analyzed
for targeted mutations in the supFG1 gene in both the epider-
mis and dermis. Mutation frequencies in the tail epidermis
treated by intradermal injection with PNA-Antp averaged
59 106 (Figure 3a), a substantial 12-fold increase com-
pared with the control PBS-treated mice and double the
frequency observed following intraperitoneal administration
of more than 10 times the amount of PNA-Antp. Mutations
in clones isolated following intradermal injections of PNA or
PNA-Antp cluster in and around the triplex-binding site,
whereas those following injection or PBS are scattered
throughout the supFG1 sequence. Mutation frequencies in
the ear epidermis following injection of PNA-Antp in the tail
were the same as the PBS controls, and those mutations were
scattered along the supFG1 sequence, not concentrated at
the triplex-binding site. Intradermal injection of PNA alone
had no effect on mutation frequency in the epidermis
compared with PBS-treated mice (Figure 3a). In the dermis,
intradermal delivery of both the PNA alone and the PNA-Antp
conjugate resulted in a 5-fold increase in targeting frequencies
compared with the PBS control (Figure 3a), and a greater
increase relative to PBS than that achieved by intraperitoneal
administration.
Gene targeting of basal keratinocytes with PNA-Antp
As keratinocytes will be the likely target of many gene-
modification strategies in the skin, we wanted to be certain
that mutations could be induced in basal keratinocytes. FITC-
PNA-Antp was injected intradermally into mouse tails and
imaged 5 hours later. In broad stretches of the epidermis
above the injected area, but not at distant sites, nearly all
epidermal nuclei were fluorescent using laser confocal fluor-
escence microscopy (Figure 3b). Basal keratinocyte nuclei
were accentuated when viewed by fluorescence microscopy
on cross sections of skin (Figure 3c). Intradermal injections of
PNA-Antp were administered into tails, and the epidermis was
isolated 10 days later, as described above. Single-cell suspen-
sions were prepared from the epidermis of several animals,
pooled, stained with antibody to keratin 5, and sorted by
fluorescence-activated cell sorting. Mutation frequency was
2-fold greater in the PNA-Antp-treated keratinocytes than in
the PBS-treated keratinocytes (Figure 3d).
Gene targeting in the back and tail epidermis of hairless mice
with TFO AG30
In anticipation of investigating different methods for delivery
or different gene-modifying molecules, we bred our reporter
gene into a hairless background and tested gene targeting
using the TFO, AG30, in back and tail skin. FITC-AG30
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Figure 3. Gene targeting in the epidermis, dermis, and tail keratinocytes of
mice after intradermal delivery of triplex-forming peptide nucleic acids
(PNAs). (a) AV mice received PNA, PNA-Antp, or phosphate-buffered saline
(PBS) by intradermal injection. Ten days later, mutations were measured in
the supFG1 transgene recovered from genomic DNA of dispase-separated
epidermis and dermis. Numbers over bars are mutant plaques over total
plaques counted, and frequencies are averages ±SEM from individual mice.
(b, c) Imaging performed 5 hours after intradermal injection of FITC-PNA-Antp
into tail. Image oriented with caudal end of tail to the right. Bars¼ 50mm. (b)
En face confocal image of a tail scale showing nuclear fluorescence in basal
keratinocytes at edges of the image and little fluorescence in the papillary
dermis in the center of the image. (c) Epifluorescence image shows nuclear
fluorescence throughout the skin, stronger in the epidermis than in the dermis.
(d) AV mice received PNA-Antp or PBS by intradermal injection. Ten days
later, mutations were measured in the supFG1 transgene recovered from
genomic DNA of keratin 5–positive (K5þ ) keratinocytes pooled from tails of
4–6 mice. Numbers over bars are mutant plaques over total plaques counted,
and frequencies are averages ±SD from two separate experiments using
pooled keratinocytes.
FA Rogers et al.
Delivery of Gene-Modifying Oligomers to Skin
www.jidonline.org 687
injected intradermally into SKHAV supFG1 transgenic mouse
tails and imaged 1 hour later revealed nuclear accumulation
in broad stretches of the epidermis, as seen using laser
confocal fluorescence microscopy (Figure 4a). Gene targeting
by AG30 in keratinocytes was measured 10 days after
intradermal injection into tails. Single-cell suspensions were
prepared from the epidermis of several animals, pooled,
stained with antibody to keratin 5, and sorted by fluores-
cence-activated cell sorting. Mutation frequency was 4-fold
greater in keratin 5–positive keratinocytes from tails treated
with AG30 than in those from tails treated with PBS
(Figure 4b). The larger surface that back skin provides com-
pared with tail would be advantageous for testing. To demon-
strate that a gene-targeting oligomer has biological activity in
skin other than in tail skin, AG30 was injected intradermally
into the backs of SKHAV mice and the whole epidermis
harvested 10 days after the second injection. AG30 induced a
2.7-fold increase in the frequency of mutation (19.5105)
compared with PBS (7.1105) in the back epidermis
(Figure 4c), which is the same fold increase seen in the tail
epidermis in this experiment (Figure 4d). Mutation frequencies
in the ear epidermis following injection of AG30 in the tail
were the same as the PBS controls, and those mutations were
scattered along the supFG1 sequence, not concentrated at the
triplex-binding site.
DISCUSSION
These studies extend previous reports that systemically admi-
nistered, sequence-specific TFOs target the skin (Vasquez
et al., 2000) and confirm that the transduction peptide,
Antp, enhances the in vivo efficacy of sequence-specific,
gene-modifying PNAs (Rogers et al., 2012). Gene targeting
by TFMs is now well established in cultured cells and in mice
in vivo. Experiments in this report add two important and
novel observations to this growing literature. First, local
delivery of these gene-modifying compounds can be at least
as effective as systemic delivery. Local delivery will be
important in future efforts aimed at increasing efficiency of
targeting, reducing cost, and minimizing targeting or toxicity
to off-target cells or tissues. Second, to our knowledge, there
has been no previous demonstration that TFMs can induce
sequence-specific gene modification in a keratinocyte or, for
that matter, in any epithelial cell. It is now clear that systemic
administration of AG30 or PNA-Antp targets whole tissues
(Vasquez et al., 2000; Rogers et al., 2012) and bone marrow–
derived cells, including hematopoietic stem cells and myeloid
and lymphoid cells (Rogers et al., 2012). Analysis of whole
tissues leaves open the question of whether some non-
epithelial cell type common to the tissues targeted, such as
endothelial cells, fibroblasts, or migratory bone marrow–
derived cells, were the modified cells. Our studies now
demonstrate that TFMs target genes in both the epidermis
and dermis, and that at least some of the targeted cells in the
epidermis are basal keratinocytes. This result implies that
in vivo local delivery of TFMs has the potential to permanently
modify genes that cause disease in the epidermis.
Proliferating keratinocytes might be expected to be espe-
cially susceptible to TFM-mediated gene modification because
it is well established that triplex-mediated targeting strongly
favors cells passing through the S or M phases of the cell cycle
(Majumdar et al., 2003). That these targeted cells would
persist for more than a week after TFM delivery, the time it
takes for mouse epidermis to completely turn over, could
not be anticipated—persistence that long implies that the
TFM-induced gene modifications that we measured originated
in proliferating, not post mitotic, cells or in cells committed
to differentiate. The lower targeting frequency in keratin
5–positive keratinocytes compared with that in intact epider-
mis is probably explained by epidermal kinetics; over time, an
increasing fraction of targeted, transient-amplifying basal cells
commit to differentiation and are desquamated. For gene
modifications to become permanent within the epidermis,
keratinocyte stem cells will need to be targeted, which may
require an additional therapeutic step of inducing those stem
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Figure 4. Gene targeting in the tail and dorsal epidermis of hairless mice
after intradermal delivery of the triplex-forming oligonucleotide AG30.
(a) Confocal fluorescence microscopy of the epidermis performed 1 hour after
intradermal injection of FITC-AG30. The caudal end of the tail is in the upper
right corner and nuclear fluorescence is seen in the en face confocal slice that
goes through basal keratinocytes at the edges of a tail scale. Bar¼50mm. (b)
SKHAV mice received AG30 or phosphate-buffered saline (PBS) by intradermal
injection. Ten days later, mutations were measured in the supFG1 transgene
recovered from genomic DNA of keratin 5–positive (K5þ ) keratinocytes
pooled from tails of 4–6 mice. (c, d) SKHAV mice received AG30 or PBS by
intradermal injection. Ten days later, mutations were measured in the supFG1
transgene recovered from genomic DNA of (c) tail or (d) back epidermis.
Numbers over bars are mutant plaques over total plaques counted, and
frequencies are averages ±SEM (in c and d) from individual mice. TFM,
triplex-forming molecule.
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cells to divide just prior to administering the TFM. It is
possible that the PNA-Antp or the AG30 also targeted
supFG1 in post-mitotic keratinocytes or other cells in the
epidermis, such as melanocytes or dendritic cells, and
contributed to the higher targeting seen in the whole
epidermis. This seems unlikely, as those cells are generally
nonmitotic, and there is no evidence that active transcrip-
tion of the transgene, another way of making a gene
accessible for targeting (Macris and Glazer, 2003), occurs
in the epidermis of these animals.
Two different TFMs that target the same supFG1 sequence
were used in our experiments. TFMs bind to the major groove
in polypurine:polypyrimidine stretches of duplex DNA in a
sequence-specific manner according to a well-established
binding ‘‘code’’ (Letai et al., 1988; Knauert and Glazer,
2001). Polypurine TFOs, such as AG30, bind in a 50 to 30
orientation antiparallel to the purine strand of the duplex, and
polypyrimidine TFOs bind parallel to the purine strand of the
duplex. PNAs form triplex DNA according to the same base-
binding code as TFOs, but utilize an amide backbone rather
than a phosphodiester backbone, giving them several advan-
tages including increased binding affinity and resistance to
nucleases (Nielsen, 2010). Compared with TFOs, delivery of
PNAs to cells in culture has required more extreme measures,
such as cell permeabilization with streptolysin-O (Faruqi
et al., 1998) or electroporation. We had previously shown
that covalent coupling of the PNA to the cell-penetrating
peptide from Antp increased uptake and targeting efficiency
in vitro (Rogers et al., 2004) and in vivo (Rogers et al., 2012).
We now show that this peptide greatly increases targeting of
epidermal keratinocytes in vivo. In contrast, the Antp peptide
did not improve targeting of dermal cells. These results
emphasize that delivery of gene-targeting oligomers may be
very different in vivo than in vitro, and that delivery properties
are cell-type specific. Uptake and biological activity in the
dermis of the PNA lacking the Antp is consistent with at least
one other example of in vivo biological activity of an un-
modified PNA used to induce exon skipping in the dystrophin
gene in muscle cells (Yin et al., 2008).
Taken together, experiments reported here establish the
supFG1 transgenic mouse as a useful and robust model in
which to test and compare different methods of local delivery
and biological efficacy of different gene-modifying small
molecules to keratinocytes. Local delivery of a therapeutic
agent could be advantageous in several ways, including the
potential for increased local concentration and decreased side
effects in nontarget tissues. It has been suggested that high
hydrodynamic pressure is important for delivering small
interfering RNA by intradermal injection into mouse paw
(Gonzalez-Gonzalez et al., 2010). Our finding that gene
modification occurred to the same extent in back skin as in
tail skin following intradermal injection, where delivery of
50ml should result in quite different post-injection pressures,
implies that pressure may not be necessary for delivering
gene-modifying molecules to the epidermis.
To date, triplex-mediated targeting of DNA occurs at low
frequency. Some rare events, however, can have a clinically
significant impact. In several instances of epidermolysis
bullosa, spontaneous heritable genetic events in keratinocytes
lead to expanding, clonal regions of skin that do not blister
(Jonkman et al., 1997; Smith et al., 2004; Jonkman and
Pasmooij, 2009). In ichthyosis with confetti caused by a rare
class of mutations in KRT10, spontaneous loss of heterozygo-
sity eliminates the mutant keratin gene through a recombination
event that results in expanding clones of normal-appearing
skin (Choate et al., 2010). In diseases such as epidermolysis
bullosa and ichthyosis with confetti, low-frequency gene-
correction strategies, such as TFM-mediated gene targeting,
could have a substantial therapeutic impact.
MATERIALS AND METHODS
Triplex-forming oligomers
PNA oligomers were obtained from BioSynthesis (Lewisville, TX). The
PNA oligomer, used for targeting the supFG1 gene, was synthesized
with the sequence JJJ JJT TJJ T-O-O-O-TCC TTC CCC C (Lys)3 (O¼
8-amino-2,6,dioxaoctanoic acid) and designed to bind as a clamp to
the homopurine strand of positions 167–176 of supFG1, as previously
described (Faruqi et al., 1998; Rogers et al., 2012). Pseudoisocytosine
(J), which mimics N-3 protonated cytosine, was used to ensure
pH-independent binding to G in the Hoogsteen mode of triplex
formation in the PNA:DNA:PNA triplex. The cell-penetrating peptide,
Antp, was covalently linked to the PNA at the C-terminal lysine via
continuous synthesis with the following sequence, JJJ JJT TJJ T-O-O-
O-TCC TTC CCC C-O-O-KKKKKWKMRRNQFWIKIQR (PNA-Antp).
For the labeled PNA-Antp conjugates, FITC was conjugated to the
PNA at the N terminus via two O linkers. The DNA oligomer,
AG30, was prepared by Midland Certified Reagent (Midland, TX)
with a 30-proplyamine and is designed to bind to the homopurine
strand of positions 167–196 of supFG1 as previously described
(Vasquez et al., 2000). FITC was covalently linked to the 50 end
of AG30.
Mice
The AV supFG1 mice were derived in a CD1 background (Charles
River Laboratories, Wilmington, MA), as described (Rogers et al.,
2012). DNA dot-blot analysis demonstrated B50 copies of the l
shuttle vector DNA in their genomes (data not shown). The presence
or absence of the supFG1 reporter gene in the resulting pups was
determined by PCR as described previously (Narayanan et al., 1997).
SKHAV supFG1 mice were derived by breeding AV mice with
SKH1 mice (Charles River Labs, Troy, NY) and back-crossing
transgenic offspring with SKH1 until the transgene, identified
by PCR as described above, was in a hairless background. All
procedures were conducted according to the animal protocols
approved by the Yale University Institutional Animals Care and
Use Committe, using the guidelines set by the Institutional Animal
Care and Use Committees of the National Institutes of Health and
Yale University.
Imaging
Transgenic AV or SKHAV mice were injected intradermally in the tail
with FITC-PNA-Antp or FITC-AG30, 10mg in 50ml PBS. Mice were
anesthetized with ketamine–xylazine, and en face images of living
tissue in vivo were obtained 1 and 5 hours after treatment using a
VivaScope 2500 (Lucid, Henrietta, NY) confocal imager equipped with
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a 630-nm reflectance laser and a 488-nm fluorescence laser(Gonzalez-
Gonzalez et al., 2011). Aquasonic H100 (Parker laboratories, Fairfield,
NJ) ultrasound transmission gel was used as immersion medium
between the objective lens and the tissue cassette. The mouse tail
was placed over the glass window of the tissue cassette after adding
Crodamol STS (Croda, Edison, NJ) as index-matching fluid (index of
refraction 1.47). The Z-depth position was adjusted using the 630-nm
reflectance laser to identify the stratum corneum. The 488-nm laser
was then used to obtain Z stacks of 750 750mm2 slices of 5mm
thickness. Images shown are from slices in which most of the cells
are basal or spinous keratinocytes. Mice were also killed, and
tissue samples were harvested, embedded in O.C.T. embedding
medium (Sakura, Tokyo, Japan), and frozen. Tissue sections (6 mm)
were prepared, mounted onto glass slides, and examined by
fluorescence microscopy using a Zeiss Axiovert 200 microscope
and the AxioVision 45 software (Carl Zeiss, Thornwood, NY).
TFO delivery to mice
Intraperitoneal injections of PNA (20 mg kg 1), PNA-Antp
(20 mg kg 1), or PBS were administered to AV mice at 2–3 weeks
of age in a 200-ml solution of PBS. Injections were given on days 1
and 3, at the same time each day, and tissue was harvested 10 days
after the last treatment, according to a recently reported protocol
known to successfully target other organs (Rogers et al., 2012).
Intradermal injections of PNA-Antp (10 mg), AG30 (50 mg), or
PBS were given to AV or SKHAV mice at 3 weeks of age in a
volume of 50 ml PBS. Injections were given on days 1 and 3, at the
same time each day, and tissue was harvested 10 days after the
last treatment.
Tissue preparation
Tail or back skin in 1 2cm pieces was removed to fascia and, where
indicated, epidermis was separated from the dermis by overnight
exposure at 4 1C to 2.5% Dispase II (Roche, Indianapolis, IN) in PBS
(Adams et al., 2005). To isolate keratin 5–positive keratinocytes,
epidermal sheets were incubated in 0.25% trypsin for 10 minutes at
37 1C, filtered sequentially through 100- and 40-mm strainers (BD
Biosciences, San Jose, CA), fixed with Cytofix/Cytoperm (BD Bio-
sciences) for 30 minutes at room temperature, washed with Perm/
Wash (BD Biosciences), incubated with rabbit anti-mouse keratin 5
(Neomarkers-Thermo Fisher, Kalamazoo, MI) for 30 minutes at 4 1C,
washed, incubated with FITC-conjugated anti-rabbit IgG (BD Bio-
sciences) for 20 minutes at 4 1C, and washed again. Fluorescence-
activated cell sorting analysis was performed using a FACSVantage SE
(BD Biosciences). High-molecular genomic DNA pooled from 6–8
mice was isolated from these keratin 5–positive cells and analyzed for
induction of mutation.
supFG1 mutagenesis assay
Genomic DNA was isolated from tissues or cells and analyzed for
induction of mutations as previously described (Vasquez et al., 2000;
Rogers et al., 2012). Briefly, genomic DNA was incubated with l
in vitro packaging extracts for shuttle vector rescue and reporter
analysis by a blue–white bacterial screen and sequencing of repre-
sentative mutant plaques to characterize the types of mutations
induced by TFO treatment. Each treatment group consisted of three
mice, and SEs were calculated for the mutation frequency values as
indicated by the error bars, except for the pooled keratin 5–positive
cells in the PNA-Antp experiment, in which the frequencies are the
mean of two experiments ±SD.
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